Skip to main content

Argenica Therapeutics with Proactive at the ASX Small and Mid-Cap Conference

--News Direct--

Argenica Therapeutics Ltd (ASX: AGN) CEO Liz Dallimore speaks with Proactive from the ASX Small and Mid-Cap Conference March 2023. The company is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Its lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.